Economy
Financial Markets
Energy & Commodities
Industries
Stocks / IPOs
Real Estate
Company - Domestic
Company - Overseas
R&D
Industrial Parks

 
Company - Domestic
 Search News  Or
Lummy Pharmaceutical's shares up 66.36% at debut on ChiNext

Oct. 30, 2009 (China Knowledge) - Chongqing Lummy Pharmaceutical Co Ltd<300006>, a Chongqing-based bio-pharmaceutical firm, debuted on the ChiNext Board on the Shenzhen Stock Exchange today, becoming one of the first companies to trade on the Nasdaq-style board.

Shares of the company opened at RMB 27.45, a price 66.36% higher than the IPO price, while the Shenzhen Component Index opened 1.92% higher at 12427.10 points.

The company raised RMB 144 million by issuing up to 23 million shares, or 25% of its enlarged capital. The underwriter of the offering was Sinolink Securities Co Ltd<600109>.

Lummy Pharmaceutical is a technology-based pharmaceutical maker focusing on the research, development, manufacture and sales of new drugs. Its net profit was RMB 28.33 million in the third quarter of this year, with return on equity standing at 5.52%.

Shares of Lummy Pharmaceutical skyrocketed 99.64% to RMB 32.94 and were currently suspended from trading on the ChiNext.







Copyright © "2013" www.chinaknowledge.com

Send feedback or comments to: news@chinaknowledge.com

For more news, financial weekly reports, business guides to China, Market Research Reports and other premium information, subscribe to China Knowledge today

To access our page on Bloomberg, type CKFI (GO)

 Our Professional Services
 News Archive
About Us | CSR | Media Center | E-Newsletter | E-Store | Contact Us | Feedback | Sitemap | Privacy Policy | Terms of Use  

           Copyright © 2014 China Knowledge Online. All Rights Reserved